Fig. 2.

New onsets, incidences, and prevalences of nausea, vomiting, and diarrhea events from initiation of treatment to week 52, measured at 2-week intervals. Arrows denote weeks at which dose escalation steps occurred. Line marker color indicates the planned final dose (i.e., treatment arm), while line color denotes the actual dose administered at a specific point in time. All patients began treatment with a once-weekly dose of 0.75 mg for a period of 4 weeks before gradually escalating to the target dose of 1.5, 3.0, or 4.5 mg at 4-week intervals